In addition, a prospective study was conducted to determine whether changes in adiponectin levels were observed in the severe AD group that showed clear clinical improvement after treatment with dupilumab, a novel interleukin (IL)-4 receptor alpha antagonist targeting and blocking IL-4 and IL-13 molecules [8]. This evidence concerns the gene IL13 and Alzheimer disease.